ERBB2 and ductal breast carcinoma in situ: A loss of, or undetectable, Her2 protein levels in benign lesions suggests that its amplification or overexpression occurs in the transition from hyperplasia to DCIS, suggesting that overexpression is considered significant in early malignant progression [46].